Physician profile
Michael A Henderson
NPI 1639125495
$8,444.11
in general payments reported to CMS, 2019-2025
45 companies · $808 in 2025
The $808 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,093 · 2020: $1,311 · 2021: $1,072 · 2022: $1,100 · 2023: $1,219 · 2024: $842 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,850 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,850.23 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,270.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,057.24 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $981.50 | 2019-2025 | |
| Abbvie INC. | $689.22 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $578.80 | 2019-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $537.32 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $421.67 | 2019-2023 | |
| Lilly USA, LLC | $340.60 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Abbott Laboratories | $292.33 | 2021-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $232.16 | 2019-2023 | |
| Amgen INC. | $231.55 | 2019-2024 | Otezla, Repatha |
| Amarin Pharma, INC. | $172.29 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $144.86 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.09 | 2019-2022 | |
| Genentech USA, INC. | $104.20 | 2019-2020 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $99.17 | 2023-2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $97.58 | 2019-2025 | Eliquis |
| Phathom Pharmaceuticals, INC. | $92.72 | 2023-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $80.38 | 2019 | |
| Allergan, INC. | $77.78 | 2019-2020 | |
| Inspire Medical Systems, INC. | $72.94 | 2023-2024 | Inspire |
| Otsuka America Pharmaceutical, INC. | $71.82 | 2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $71.46 | 2022-2023 | |
| Astellas Pharma US INC | $63.97 | 2021-2025 | Veozah |
| Eisai INC. | $55.45 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $54.64 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.14 | 2019-2021 | |
| Radius Health, INC. | $35.44 | 2019 | |
| Dexcom, INC. | $33.60 | 2021-2023 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $33.40 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Daiichi Sankyo INC. | $32.58 | 2019-2023 | Injectafer |
| Sunovion Pharmaceuticals INC. | $27.95 | 2021 | |
| Mylan Specialty L.P. | $27.46 | 2019 | |
| Stryker Corporation | $20.48 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.38 | 2021 | |
| Silk Road Medical, INC. | $20.13 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Idorsia Pharmaceuticals US INC | $18.21 | 2024 | Quviviq |
| Nevro Corp. | $17.93 | 2022 | |
| Mannkind Corporation | $16.32 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.09 | 2022 | |
| Dynavax Technologies Corporation | $15.63 | 2025 | Heplisav-B |
| Esperion Therapeutics, INC. | $14.94 | 2020 | |
| Exact Sciences Corporation | $13.73 | 2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $13.14 | 2024 | |
| Zyla Life Sciences, INC. | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.